Ailing Song, Hai Jiang, Liang Guo, Shanshan Wu, Am J Transl Res 2021;13(5):5156-5164

Objectives: The study discussed and analyzed the combined efficacy of adalimumab with granulocyte and monocyte adsorption apheresis (GMA) method on patients with ulcerative colitis (UC) and the repair of intestinal mucosal lesion. Methods: 60 UC patients in moderate-to-severe active phase that hospitalized from January 2017 to March 2020 were chosen and randomly classified into observation group (n=30) and control group (n=30). The control-group patients received GMA treatment, and the observation-group patients received combination therapy of GMA and adalimumab. The therapeutic efficacy, laboratory indicators, changes of serum inflammatory factors, and intestinal mucosal barrier impairment in two sets of participants were compared. Results: The comprehensive effective rate of clinical treatment was remarkably higher in observation group than that in control group (P<0.05). CRP and ESR of the two groups in post- treatment were notably lower than those before treatment (P<0.05), while Hb and ALB in post-treatment increased significantly than in pre-intervention (P<0.05); CRP in observation group after treatment was remarkably lower than that in control group (P<0.05), while no significant difference was noticed in ESR, ALB and Hb between the two groups (P>0.05). The serum inflammatory factors in observation group in post-treatment were significantly lower than those in the control group (P<0.05). The scores of PCT, DAO and intestinal mucosa in two sets of participants in post-treatment were dramatically lower than those in pre-treatment (P<0.05), and the scores in observation group after treatment were notably lower than those in the control group (P<0.05). Conclusions: The combined efficacy of adalimumab with GMA on UC patients can improve the clinical curative efficacy, effectively reduce the inflammatory factors, which is beneficial to the repair of intestinal mucosal barrier function, and worthy of clinical application.

https://pubmed.ncbi.nlm.nih.gov/34150104/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205815/pdf/ajtr0013-5156.pdf

Yuki Isami,Yuriko Kawase,Akari Kondo,Wataru Akita,Koji Yasuda,Takeshi Matsutani,Hiroshi Mitsui

J Dermatol. 2020 May;47(5):e213-e215. doi: 10.1111/1346-8138.15303. Epub 2020 Mar 11.

letter.

https://pubmed.ncbi.nlm.nih.gov/32162361/

Marta Velasco Rodríguez-Belvís ¹, Javier Francisco Viada Bris ¹, Laura Palomino Pérez ¹, Rosa Ana Muñoz Codoceo ¹ , inflamm Bowel Dis. 2019 Jun 18;25(7):e82-e83.

https://pubmed.ncbi.nlm.nih.gov/30698787/

Yong Eun Park ¹, Jae Hee Cheon ^1 2 , Korean J Intern Med. 2018 Jan;33(1):1-19.

Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

https://pubmed.ncbi.nlm.nih.gov/29207867/

Satoshi Tanida ¹, Tsutomu Mizoshita ¹, Hirotada Nishie ¹, Keiji Ozeki ¹, Takahito Katano ¹, Eiji Kubota ¹, Hiromi Kataoka ¹, Takeshi Kamiya ¹, Takashi Joh ¹ , J Clin Med Res. 2015 Nov;7(11):884-9.

It was concluded that combination therapy with ADA plus intensive GMA is useful for induction of clinical remission in refractory UC patients, and is well tolerated.

https://pubmed.ncbi.nlm.nih.gov/26491502/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596271/pdf/jocmr-07-884.pdf